EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Canagliflozin Reprograms the Aging Hippocampus in Genetically Diverse UM ‐ HET 3 Mice and Attenuates Alzheimer's‐Like Pathology

Hashan Jayarathne, Dulmalika Herath Manchanayake iD, Ryan Sullivan, Nina Chimienti, Omar Kadri, Katherine Gurdziel, Seongho Kim, Hyejeong Jang, Brett C Ginsburg, Richard A Miller, Shoshana Yakar, Marianna Sadagurski

Aging Cell · 2025-12 · 24 (12)

DOI: 10.1111/acel.70255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging Cell, online erschienen am 05.10.2025. Verfasst von Hashan Jayarathne und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Wayne State University, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Hippocampus, Alzheimer Disease, Canagliflozin, Aging. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, NIA NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aging is the strongest risk factor for cognitive decline and Alzheimer's disease (AD), yet the mechanisms underlying brain aging and their modulation by pharmacological interventions remain poorly defined. The hippocampus, essential for learning and memory, is particularly vulnerable to metabolic stress and inflammation. Canagliflozin (Cana), an FDA‐approved sodium‐glucose co‐transporter 2 inhibitor (SGLT2i) for type 2 diabetes, extends lifespan in male but not female mice, but its impact on brain aging is unknown. Here, we used a multi‐omics strategy integrating transcriptomics, proteomics, and metabolomics to investigate how chronic Cana treatment reprograms brain aging in genetically diverse UM‐HET3 mice. In males, Cana induced mitochondrial function, insulin and cGMP–PKG signaling, and suppressed neuroinflammatory networks across all molecular layers, resulting in improved hippocampal‐dependent learning and memory. In females, transcriptional activation of neuroprotective pathways did not translate to protein or metabolite‐level changes and failed to rescue cognition. In the 5xFAD AD model, Cana reduced amyloid plaque burden, microgliosis, and memory deficits in males only, despite comparable peripheral glucose improvements in both sexes. Our study reveals sex‐specific remodeling of hippocampal aging by a clinically available SGLT2i, with implications for AD pathology and lifespan extension, and highlights Cana's potential to combat brain aging and AD through sex‐specific mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HippocampusAlzheimer DiseaseCanagliflozinAgingAnimalsMiceMaleFemaleDisease Models, AnimalMice, Transgenic

Stichwörter der Autor:innen

Alzheimer's diseaseCanagliflozinaging brainhippocampuslongevitymetabolism

Substanzen

Canagliflozin

Autor:innen und Institutionen

  • Department of Biological Sciences, Wayne State University, Detroit, Michigan, USA.
  • Institute of Environmental Health Sciences, Integrative Biosciences Center, Wayne State University, Detroit, Michigan, USA.
  • Department of Oncology, School of Medicine, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA.
  • Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, San Antonio, Texas, USA.
  • Department of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Molecular Pathobiology, David B. Kriser Dental Center, New York University, New York, New York, USA.

ORCID-Profile: Dulmalika Herath Manchanayake

Förderung

  • NIEHS NIH HHS
  • NIA NIH HHS
  • NIH HHS
  • NCI NIH HHS
  • NIDDK NIH HHS
  • CURES
  • Impetus Grants for Longevity Research
  • Cures Within Reach

Zitieren

APA

Jayarathne, H., Manchanayake, D. H., Sullivan, R., Chimienti, N., Kadri, O., Gurdziel, K., Kim, S., Jang, H., Ginsburg, B. C., Miller, R. A., Yakar, S., & Sadagurski, M. (2025). Canagliflozin Reprograms the Aging Hippocampus in Genetically Diverse UM ‐ HET 3 Mice and Attenuates Alzheimer's‐Like Pathology. Aging Cell, 24(12). https://doi.org/10.1111/acel.70255

Vancouver

Jayarathne H, Manchanayake DH, Sullivan R, Chimienti N, Kadri O, Gurdziel K, et al. Canagliflozin Reprograms the Aging Hippocampus in Genetically Diverse UM ‐ HET 3 Mice and Attenuates Alzheimer's‐Like Pathology. Aging Cell. 2025;24(12). doi:10.1111/acel.70255

BibTeX
@article{Jayarathne2025,
  author = {Jayarathne, Hashan and Manchanayake, Dulmalika Herath and Sullivan, Ryan and Chimienti, Nina and Kadri, Omar and Gurdziel, Katherine and Kim, Seongho and Jang, Hyejeong and Ginsburg, Brett C and Miller, Richard A and Yakar, Shoshana and Sadagurski, Marianna},
  title = {Canagliflozin Reprograms the Aging Hippocampus in Genetically Diverse UM ‐ HET 3 Mice and Attenuates Alzheimer's‐Like Pathology},
  journal = {Aging Cell},
  year = {2025},
  volume = {24},
  number = {12},
  doi = {10.1111/acel.70255}
}
Kostenlos starten →